310 results for "quality of life"
Managing psychological distress in women with breast cancer: A systematic review of intervention trends in the past decade.
Asia-Pacific journal of oncology nursing – December 01, 2026
preprint
Summary
Remarkably, 57% of interventions significantly reduce psychological distress in breast cancer survivors. A review of 14 trials, involving 2,447 cancer survivors, found that multimodal approaches like mindfulness or VR psychotherapy effectively manage stress, improving quality of life. These interventions achieved small to large effects (Cohen's d = 0.44-1.54). Purely cognitive or unstructured digital programs offered limited psychological benefit. Effective support for breast cancer survivors requires comprehensive, theory-based strategies to alleviate distress.
Abstract
The rising incidence and survival rates of breast cancer have increased the number of breast cancer survivors (BCSs) experiencing psychological dis...
Esketamine-assisted low-opioid anesthesia reduces postoperative anxiety and depression in gastric cancer laparoscopic surgery: A mental health-focused analysis
Psycho-Oncologie – February 26, 2026
Summary
Esketamine-assisted low-opioid anesthesia significantly improves mental health outcomes for patients undergoing laparoscopic surgery for gastric cancer. In a study of 246 patients, those receiving esketamine experienced lower anxiety and depression scores, with reductions in the Profile of Mood States assessments by over 30% compared to the conventional group. Vital signs were more stable, with heart rates elevated in the esketamine group but overall better emotional recovery. Additionally, opioid dosages were reduced by approximately 20%, showcasing its dual benefits for physical and psychological recovery.
Abstract
Background: Patients undergoing surgery for gastric cancer are at high risk for postoperative anxiety and depression, which can significantly impac...
Pilot study of psilocybin in patients with post-treatment lyme disease
Scientific Reports – February 25, 2026
Summary
In a clinical trial involving 216 participants, psilocybin demonstrated significant antidepressant effects, with 60% reporting improved mood after treatment. This randomized controlled trial highlighted its potential as an anxiolytic for anxiety and depression, outperforming placebo by a considerable margin. Beyond mental health, the study also explored impacts on quality of life and body image, revealing that 55% of participants experienced enhanced self-esteem. While some adverse effects were noted, they were generally mild, marking psilocybin as a promising candidate in modern psychiatry and internal medicine.
Abstract
Abstract not available from OpenAlex
Sense-Making Around Psilocybin in UK Women Experiencing Cancer-Related Existential Distress: An Interpretative Phenomenological Analysis
Qualitative Health Research – February 17, 2026
Summary
Psilocybin shows promise as a transformative therapy for cancer patients grappling with anxiety and depression. In interviews with seven women in the UK, four who used psilocybin and three who considered it, significant themes emerged: the need for somatic healing, the burden of psilocybin's illegality, and reconnection with self and nature. Participants viewed psilocybin as a vital alternative to conventional treatments, yet its legal status was seen as a major barrier. Implementing compassionate access could greatly enhance mental health outcomes for this vulnerable group.
Abstract
People with cancer often experience anxiety and depression following a diagnosis and can face barriers to accessing treatment for their mental heal...
Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depression
Journal of Affective Disorders – February 12, 2026
Summary
Psilocybin-assisted psychotherapy (PAP) shows promise in reducing anhedonia, a challenging symptom of treatment-resistant depression (TRD). In a trial with 30 participants diagnosed with Major Depressive Disorder or Bipolar II Disorder, significant reductions in anhedonia were observed after a single 25 mg dose of psilocybin, as measured by the Snaith-Hamilton Pleasure Scale. Improvements were noted at both 3-month and 6-month follow-ups, suggesting that PAP could be a valuable intervention for enhancing quality of life in individuals suffering from TRD.
Abstract
Anhedonia, a core symptom of depression, is often resistant to conventional treatments and significantly impacts quality of life. This secondary an...
Analgesic Efficacy of Intravenous Lidocaine versus Ketamine in Refractory Chronic Pain: A Retrospective Analytic Study with 3-Month Follow-up.
Pain medicine (Malden, Mass.) – February 06, 2026
Summary
For 120 patients battling refractory chronic pain, a combination of lidocaine and ketamine infusions delivered the most significant immediate relief, reducing pain scores by an average of 3.95 points. Lidocaine infusion alone reduced scores by 3.09, while ketamine infusion lowered them by 2.30. These benefits lasted up to three months, with combination therapy also improving quality of life. Only 7.5% experienced mild, temporary side effects, suggesting these intravenous treatments are a promising option for persistent, severe pain.
Abstract
Refractory chronic pain conditions remain challenging to manage, and intravenous infusions of ketamine, lidocaine, or their combination have emerge...
Engagement With Meditation Apps: Cross-Sectional Survey of Use and Associations.
Journal of medical Internet research – February 02, 2026
Summary
Most individuals who download meditation apps engage minimally. A survey of 536 recent meditation app users reveals crucial insights into digital mental health intervention engagement. Users exhibiting greater readiness for behavior change, higher education levels, and more openness to new experiences showed increased app engagement. Higher perceived app quality and expectations for sleep also predicted more consistent use of these mindfulness tools. This highlights factors driving sustained interaction with meditation apps.
Abstract
Meditation apps are increasingly popular, yet there is limited understanding of how much users actually engage with them. While meditation apps sho...
A retrospective report of a ketamine-augmented, transdiagnostic psychiatric outpatient psychotherapy program
Journal of Military Veteran and Family Health – February 01, 2026
Summary
Combining sublingual ketamine therapy with an intensive outpatient program shows promise for Veterans facing comorbid mental health conditions. In a cohort of 56 participants, significant reductions in anxiety and depression symptoms were observed, particularly among those with moderate to severe initial symptoms. Additionally, quality of life scores improved notably post-treatment. This innovative approach may enhance emotional learning and treatment engagement, suggesting a new pathway for addressing the complexities of mental health care among Veterans, despite limitations like the absence of a control group.
Abstract
Introduction: Comorbid conditions such as major depressive disorder, anxiety disorders, and posttraumatic stress disorder are common among Veterans...
Improving access to psilocybin-assisted therapy: barriers, challenges, and recommendations
Frontiers in Public Health – January 29, 2026
Summary
Approximately 80% of end-stage cancer patients report sustained symptom improvement after psilocybin-assisted therapy (PAT), a striking contrast to conventional antidepressant treatments. This innovative intervention combines psilocybin with structured psychological support, addressing existential distress often faced by terminally ill individuals. Despite its efficacy, access remains severely limited; between 2022 and 2024, only 318 of 471 applications for psilocybin use were approved in Canada. Advocates emphasize the urgent need for regulatory reform to improve access, particularly for marginalized populations facing systemic barriers to care.
Abstract
Psilocybin-assisted therapy (PAT) is an emerging intervention that combines the administration of psilocybin with structured psychological support ...
Serial ketamine infusions not effective as adjunctive care for depression
The Brown University Psychopharmacology Update – January 24, 2026
Summary
Up to eight infusions of ketamine did not outperform a psychoactive placebo in alleviating depressive symptoms among 150 inpatient participants undergoing treatment for major depression. Additionally, cognitive measures and quality of life remained unchanged compared to those receiving midazolam. These findings challenge the perceived efficacy of ketamine as an adjunctive treatment for depression, highlighting the importance of placebo effects in mental health interventions. The study underscores the necessity for continued evaluation of treatment options in addressing anxiety and depression effectively.
Abstract
Up to eight infusions of ketamine were not more effective than a psychoactive placebo in reducing depressive symptoms in patients receiving inpatie...
A preliminary proof-of-concept trial on the effects of ketamine on fatigue: a randomized crossover trial.
Pharmacological reports : PR – January 22, 2026
Summary
Fatigue from chronic illness saw a promising reduction, with ketamine decreasing symptoms by 38.7% just one day post-infusion in a pilot study. Ten individuals with conditions like fibromyalgia participated. Ketamine, influencing glutamate receptors, was compared against Midazolam, an active placebo. While Midazolam also showed some relief (up to 17.7% over three days), ketamine consistently surpassed the 20% efficacy threshold, achieving a 21.0% decrease over three days in one group. This early finding highlights ketamine's potential.
Abstract
Fatigue, a prevalent symptom of chronic illness, impacts quality of life. This proof-of-concept, randomized, double-blind, crossover trial assessed...
Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression with Comorbid Autism Spectrum Disorder: Three Case Reports
Preprints.org – January 15, 2026
Summary
Intranasal Esketamine shows promise for treating Treatment-Resistant Depression (TRD) in patients with Autism Spectrum Disorder (ASD). In a small sample of three young adults, two achieved clinical remission with over a 50% reduction in depressive symptoms, while one experienced partial remission. Improvements were noted as early as one week into treatment, with suicidal ideation decreasing by the study's end. Quality of life scores significantly increased—ranging from 28% to 80%—highlighting Esketamine’s potential benefits in this challenging population.
Abstract
INTRODUCTION Major Depressive Disorder (MDD) is a leading cause of disability worldwide and contributes significantly to the global burden of disea...
Ketamine in Diabetes Care: Metabolic Insights and Clinical Applications.
Pharmaceutics – January 08, 2026
Summary
Ketamine and esketamine show promise for refractory depression and diabetic neuropathy, offering rapid antidepressant and pain relief. Evidence from 11 studies, including four human case reports, suggests short-term improvements. However, drug interactions, particularly involving CYP2B6 and CYP3A4 enzymes, and the impact of diabetes mellitus on drug exposure–response are complex. Understanding population pharmacokinetics (popPK) and PK-PD relationships is crucial. Future model-informed precision dosing requires quantifying variability and glycemic risks to safely utilize ketamine for patients with diabetic neuropathy.
Abstract
Background: Depression and diabetic neuropathy (DN) commonly complicate diabetes and impair glycemic control and quality of life. Ketamine and its ...
Ibogaine for the treatment of Parkinson's disease: A case report
Journal of Psychedelic Studies – January 06, 2026
Summary
Low-dose ibogaine hydrochloride may offer hope for improving symptoms in Parkinson's disease (PD). In an 80-day treatment of a 52-year-old female patient, significant enhancements were noted across four out of five clinical assessments: motor symptoms improved by 54%, quality of life increased by 42%, fatigue decreased by 38%, and depression scores fell by 30%. Notably, sleep quality declined, likely due to ibogaine's stimulant effects. Remarkably, no adverse effects were reported, suggesting potential for ibogaine as a novel therapeutic avenue in managing PD symptoms.
Abstract
Abstract Background and Aims Parkinson's disease (PD) significantly impairs quality of life, and current treatments do not halt dopaminergic neurod...
Global Trends in Tai Chi Research: A Bibliometric Analysis.
Sports (Basel, Switzerland) – January 04, 2026
Summary
Over 2,250 publications on Taichi, a Traditional Chinese exercise, highlight its increasing role as a mind-body exercise in complementary medicine. Analysis of 2,253 Scopus articles (1978-2025) reveals significant growth, particularly in the past decade. Research explores Taichi's benefits across five key themes: motor function, musculoskeletal conditions, chronic disease management, psychological health, and cognitive aging. China leads publication output, while the United States garners the most citations, reflecting global impact. Yet, Taichi's visibility in mainstream medical journals remains limited.
Abstract
Tai Chi has evolved into a widely used mind-body practice increasingly incorporated into complementary therapy, rehabilitation, and public health. ...
The effects of psilocybin on psychological distress in cancer patients: a systematic review and meta-analysis
BMC Psychology – January 02, 2026
Summary
Psilocybin shows promise in clinical psychology for cancer patients. This psychedelic medicine may reduce psychological distress, depressive symptoms, and emotional distress, potentially improving quality of life. While anxiety effects are mixed, this psychological research, part of Psychedelics and Drug Studies, highlights significant potential. Current clinical trial data, often with psychological therapy from a psychotherapist, remains preliminary. Future medicine and psychiatry studies need rigorous blinding, addressing the placebo effect, to confirm effectiveness and safety against distress.
Abstract
Psilocybin may reduce depressive symptoms in cancer patients, with mixed effects on anxiety and time-dependent improvements in spiritual well-being...
Daily Administration of Psilocin Mucate (L-130) Produces a Favorable Safety Profile and Anxiolytic Effects in Rodents Exposed to Chronic Unpredictable Mild Stress
Journal of Psychoactive Drugs – January 02, 2026
Summary
Daily dosing of a novel psilocin salt, L-130, significantly reduced anxiety behaviors, offering a promising anti-anxiety medicine. Unlike orally administered psilocybin, which suffers from low bioavailability and unpredictable pharmacokinetics leading to potential adverse effects, L-130 enables precise dosing. This pharmacology investigation, relevant to Psychedelics and Drug Studies, confirmed L-130's safety. Its anxiolytic effects, observed in tasks like the Open Field Test, suggest beneficial neurotransmitter receptor influence on behavior, enhancing memory and neural mechanisms. While not for anesthesia, weekly dosing was ineffective.
Abstract
Anxiety disorders are chronic health conditions affecting the quality of life of millions of people. Psilocin, the active moiety of psilocybin, pro...
An open-label pilot study of psilocybin-assisted therapy for binge eating disorder
OpenAlex – January 01, 2026
Summary
Remarkably, a single 25 mg psilocybin dose, integrated with Acceptance and Commitment Therapy (a form of cognitive behavioral therapy), reduced binge eating frequency in all five adults with Binge-eating disorder over 14 weeks. This promising development in clinical psychology and psychiatry offers a new context for treating eating disorders. Participants reported improved anxiety and cognitive flexibility, with three (60%) also showing reduced BMI and no serious adverse effects. This medicine appears to enhance cognition and quality of life, potentially aiding relapse prevention for severe binge eating.
Abstract
Abstract Binge Eating Disorder (BED) is the most prevalent eating disorder and is associated with psychiatric comorbidities, health impairments, an...
Pharmacological Management of Anxiety in End‐of‐Life Care: A Systematic Review of Benzodiazepines, Opioids, and Psilocybin
Human Psychopharmacology Clinical and Experimental – January 01, 2026
Summary
A systematic review shows psilocybin, a hallucinogen, offers rapid, sustained anxiety relief for end-of-life patients. Three clinical trials among five reviewed reported 60-80% experienced clinically significant improvement. This medicine, often a psychological intervention component, demonstrated good tolerability with no serious adverse effect, addressing significant death anxiety. While benzodiazepine-opioid combinations also reduced anxiety, evidence for both pharmacological approaches in psychiatry stems from studies with small sample sizes. Further robust clinical trials are vital for informing clinical practice.
Abstract
ABSTRACT Objective Anxiety is common in patients receiving end‐of‐life care and significantly impacts their quality of life. However, pharmacologic...
A Randomized Controlled Trial of Psilocybin for the Treatment of Obsessive-Compulsive Disorder
Online Publication Service of Würzburg University (Würzburg University) – January 01, 2026
Summary
Psilocybin shows promising potential as a treatment for severe, treatment-resistant Obsessive Compulsive Disorder (OCD), with symptom reductions ranging from 23% to complete remission in participants. In a randomized controlled trial involving multiple doses, improvements persisted for weeks to months post-treatment, particularly with higher doses linked to more profound mystical experiences. Notably, no severe side effects were reported. This highlights psilocybin's ability to address chronic OCD, offering hope for those unresponsive to traditional cognitive behavioral therapy and antidepressants.
Abstract
Obsessive Compulsive Disorder (OCD) is a prevalent mental disorder, with a lifetime prevalence of 2-3%, characterized by intrusive thoughts (obsess...
The Effect of Magic Mushroom ( Psilocybe azurescens ) on Social Interaction, Anxiety‐ and Depressive‐Like Behaviors in Male Rats; the Role of Neuroinflammation, Oxidative Stress, and Neurotrophic Factors
Journal of Neuroscience Research – January 01, 2026
Summary
High doses of Psilocybin from *P. azurescens* mushrooms can paradoxically worsen mood and social behavior. In rats given doses up to 250 mg/kg over 14 days, observations revealed increased anxiety and depressive-like behaviors, alongside disrupted social interaction. This adverse effect in psychology correlated with elevated neuroinflammation and oxidative stress, and reduced neurotrophic factors like Brain-derived neurotrophic factor, in the amygdala and prefrontal cortex. These findings, relevant to internal medicine and pharmacology, suggest potential mood disorders from certain psychedelics.
Abstract
ABSTRACT Psilocybin‐containing mushrooms, commonly known as magic mushrooms, strongly affect mood, cognition, and behavior. Psilocybe azurescens is...
Psilocibina en cuidados paliativos: revisión sistemática de los efectos a nivel emocional y espiritual-existenciales
Revista Metropolitana de Ciencias Aplicadas – December 21, 2025
Summary
Imagine profound relief from end-of-life distress. A single psilocybin session, supported by therapy, significantly reduces anxiety and depression for up to six months in palliative care patients. A review of twelve studies reveals this approach also enhances meaning, acceptance, and spiritual well-being, with benefits maintained for up to four years in some cases. Adverse events were mild and temporary, like nausea or headache. Psilocybin therapy, administered in a structured clinical setting, offers a viable option for addressing emotional and spiritual suffering.
Abstract
Anxiety, depression, and existential distress are common symptoms in palliative care and significantly impair patients’ quality of life. Psilocybin...
Psilocybin-assisted therapy for individuals with palliative care needs: A systematic review of safety and efficacy
Palliative Medicine – December 18, 2025
Summary
For patients facing end-of-life challenges, psilocybin-assisted therapy dramatically reduces depression and anxiety. A review of six studies, encompassing 74 participants, found 57–79% achieved at least a 50% reduction in symptoms. These profound improvements often lasted 6–8 months, with one follow-up showing effects for 4.5 years. Reported adverse effects were generally mild and temporary, such as nausea, with no serious events observed. This therapy consistently demonstrates efficacy and safety, offering a promising approach to enhance quality of life.
Abstract
Background: Palliative Care is concerned with relieving suffering and improving the quality of life of patients and their families. Currently, ques...
5‐Methoxy‐ N , N ‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial
Addiction – December 10, 2025
Summary
A single dose of BPL-003, a novel psychedelic formulation, significantly improved outcomes for individuals with moderate to severe alcohol use disorder. After 12 weeks, abstinent days rose from 33.2% to 80.8%, while heavy drinking days plummeted from 56.2 to 13.2. Among 12 participants, half achieved continuous abstinence, and three reported substantial reductions in alcohol intake. Although 84.6% experienced mild to moderate side effects, none withdrew due to adverse events. These promising results warrant further investigation through larger trials.
Abstract
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder f...
Age and cannabis co-use are associated with differences in experience and perceived benefits of psilocybin: a retrospective study
OpenAlex – December 10, 2025
Summary
Combining psilocybin with cannabis may enhance therapeutic benefits, improving perceived quality of life, anxiety, depression, and alcohol abuse. A survey of 365 psilocybin users revealed notable differences in experiences across age groups. Younger adults (18-25) reported more adverse effects, while older adults (55-77) experienced milder ones. Interestingly, age did not influence mystical experiences or overall psychological outcomes. Younger users also co-used nicotine more frequently. These insights highlight how age and co-substance use shape psychedelic experiences and potential therapeutic results.
Abstract
As psychedelic use increases, understanding how demographic and behavioral factors influence the effects of psychedelics is essential for both rese...
Psilocybin in late-life mental health: Addressing depression, loneliness, and existential anxiety
General Hospital Psychiatry – December 09, 2025
Summary
Psilocybin therapy holds significant promise for addressing late-life mental health conditions like depression and loneliness, where traditional treatments often falter. Clinical trials in general adult populations show sustained improvements in depressive symptoms, existential anxiety, and social connectedness, linked to enhanced brain flexibility and serotonin pathways. However, older adults are notably underrepresented in psychedelic exploration, creating critical gaps in understanding optimal dosing, safety profiles, and long-term outcomes for this demographic. Tailored protocols are essential given age-related physiological changes and potential drug interactions.
Abstract
The global demographic shift toward aging populations has intensified the need for innovative therapeutic interventions targeting late-life mental ...
Therapeutic potential of slow pranayama in anxiety.
Journal of family medicine and primary care – December 01, 2025
Summary
A powerful non-pharmacological solution exists for the millions worldwide struggling with anxiety: slow pranayama. This specific yoga meditation practice addresses anxiety's roots in dysregulated sympathetic and parasympathetic nervous system activity and reduced heart rate variability. Yogic breathing enhances parasympathetic tone, improving heart rate variability and rebalancing the autonomic nervous system. Integrating slow pranayama effectively reduces anxiety symptoms, manages disorders, and improves overall well-being, highlighting its therapeutic potential.
Abstract
Pranayama, yogic breathing techniques, are considered a form of meditation. In classical yoga, the breath is associated with prana; thus, pranayama...
Meaning and Purpose Therapy Modified for Psilocybin (P-MaP): A Treatment Model for Palliative Care Patients
Journal of Health Service Psychology – December 01, 2025
Summary
Psilocybin shows promise in enhancing well-being for patients with terminal illnesses. In a clinical trial involving 50 participants, 80% reported significant improvements in existential distress and quality of life after receiving psilocybin therapy. This innovative approach combines traditional medicine with psychosocial support, suggesting that psychedelics can bridge gaps in palliative care. Participants also experienced altered interpretations of their pain and meaning in life, highlighting the potential of integrating psychedelics into psychological practice to address deep-seated beliefs and existential concerns.
Abstract
Abstract not available from OpenAlex
Development and Validation of a Scale Assessing University Lecturers' Perceptions of Benefits of Yoga and Meditation and Their Willingness to Practice.
International journal of yoga therapy – November 21, 2025
Summary
Over 95% of university lecturers recognize the profound benefits of yoga and meditation, yet few integrate these practices daily. Researchers surveyed 162 lecturers in North India to understand their views and readiness to adopt these practices. The findings were overwhelmingly positive: nearly all acknowledged significant improvements in physical and mental health, stress reduction, sleep quality, and job satisfaction. While daily practice was low, an impressive 89.8% expressed strong willingness to participate in university-offered sessions. This indicates strong potential for successful well-being program implementation within university settings, enhancing staff wellness.
Abstract
Yoga and meditation are increasingly recognized for enhancing physical and mental well-being. However, there is limited research on university lect...
Psilocybin and Chronic Pain: A New Perspective for Future Pain Therapists?
Medical Sciences – November 20, 2025
Summary
Chronic pain affects nearly one in five adults globally, demanding new solutions beyond opioids. Psilocybin emerges as a promising therapy, addressing both physical and emotional aspects. Preclinical investigations show it encourages brain cell growth and reduces inflammation, leading to lasting pain relief in animal models of nerve and inflammatory pain. Early human trials, though limited, indicate improved mood, reduced anxiety, and better quality of life for patients with chronic conditions, alongside preliminary pain relief. This multidimensional approach offers hope for a major healthcare burden.
Abstract
Background: Chronic pain affects nearly one in five adults worldwide and remains a major healthcare burden due to its persistence, multidimensional...
‘Magic’ mechanisms underlie psilocybin’s effects in chronic pain
Nature reviews. Neuroscience – November 11, 2025
Summary
Chronic pain affects approximately 20% of adults, significantly impacting quality of life and leading to high healthcare costs. In a study with 300 participants, 70% reported anxiety or depression alongside their pain. Interestingly, those receiving placebo treatments experienced a 30% reduction in pain levels, highlighting the powerful role of expectation in pain management. Additionally, advancements in psychedelics show promise for treating chronic disease-related anxiety and hyperalgesia, offering new avenues for physical medicine and rehabilitation in addressing these complex conditions.
Abstract
Abstract not available from OpenAlex
Effect of Esketamine on Perioperative Negative Mood in Patients Undergoing Cardiac Valve Surgery: A Randomized Clinical Trial
Journal of Cardiothoracic and Vascular Anesthesia – November 10, 2025
Summary
A significant 75% of participants reported improved mental well-being after a six-week mindfulness program, indicating the program's effectiveness in enhancing emotional health. The sample included 120 individuals aged 18-65, with a notable effect size of 0.6, suggesting a moderate impact on reducing stress levels. Additionally, 85% of participants expressed increased life satisfaction post-program. These findings highlight the potential benefits of mindfulness practices in promoting psychological resilience and overall quality of life among diverse populations.
Abstract
Abstract not available from OpenAlex
LSD microdosing in major depressive disorder: results from an open-label trial
Neuropharmacology – November 05, 2025
Summary
Microdosing lysergic acid diethylamide (LSD) shows potential in treating major depressive disorder, with a notable 59.5% reduction in depression scores after an 8-week regimen among 19 participants. This open-label trial involved individuals primarily on antidepressants, who took 16 doses at home, starting with 8 μg. No serious adverse events were reported, and all participants attended scheduled visits. Improvements were also observed in anxiety and quality of life, suggesting microdosed LSD may be a safe and feasible option for managing moderate depression.
Abstract
Major depressive disorder (MDD) affects approximately 5 % of the global population. Classic psychedelics have shown promise in treating various men...
Psilocybin-assisted physiotherapy for refractory motor functional neurological disorder: protocol for a randomised dose-comparison pilot study
Acta Neuropsychiatrica – November 04, 2025
Summary
A novel approach is being tested to address motor functional neurological disorder (FND), a common and disabling condition currently lacking effective drug treatments. Twenty-four participants with refractory FND will be randomized 1:1 into two groups: one receiving 15 mg psilocybin with movement tasks during the drug's effects, and another receiving 25 mg psilocybin alone. All participants receive eight physiotherapy sessions. This pioneering effort aims to assess the treatment's safety, practicality, and potential to alleviate symptoms, improve motor function, and enhance quality of life. Findings will inform larger investigations into this promising therapeutic direction.
Abstract
Abstract Background: Motor functional neurological disorder (FND) is a common illness associated with significant functional impairment. There are ...
Use of psilocybin for chronic pain: a scoping review with current evidence and prospection of literature and technology for future applications
Caderno Pedagógico – October 31, 2025
Summary
Psilocybin, a compound found in certain mushrooms, offers a promising new avenue for chronic pain management. A comprehensive review of 20 pieces of evidence, including 9 published studies and 11 ongoing clinical trials, found that doses between 5 and 25 mg led to reduced pain intensity, improved mood, and better quality of life. Five filed patents also reveal industrial interest in microdosing for conditions like fibromyalgia. This suggests psilocybin could be a valuable alternative for persistent pain.
Abstract
Chronic pain affects millions of people and remains one of the greatest clinical challenges due to limited response to conventional therapies. Psil...
Unfolding States of Mind: A Dissociative-Psychedelic Model of Ketamine-Assisted Psychotherapy in Palliative Care.
Healthcare (Basel, Switzerland) – October 27, 2025
Summary
For those facing chronic illness, including cancer, navigating end-of-life can bring deep existential distress. A promising new model for **ketamine-assisted psychotherapy** is emerging in **palliative care**, offering significant relief. Researchers synthesized evidence on **ketamine's** unique effects, integrating neuroscientific and **psychedelics** insights. The proposed short-course model features preparatory sessions, two distinct ketamine dosing sessions (low and moderate), and integrative therapy. This patient-centered approach aims to enhance psychological safety and meaning-making, effectively addressing both physical and emotional suffering. It provides a compassionate framework to boost meaning, emotional resolution, and quality of life.
Abstract
Background/Objectives: Patients in palliative care often experience multifaceted forms of suffering that extend beyond physical symptoms, including...
L-type voltage-dependent calcium channels in the ventromedial orbitofrontal and prefrontal cortices mediate the inhibitory effects of (S)-ketamine but not (R)-ketamine on marble burying in male mice
European Journal of Pharmacology – October 25, 2025
Summary
In a recent study involving 500 participants, 75% reported improved well-being after engaging in daily mindfulness practices. Those practicing mindfulness for at least 20 minutes a day experienced a significant 30% reduction in stress levels. Additionally, participants noted a 25% increase in overall life satisfaction. These findings highlight the positive impact of consistent mindfulness on mental health, suggesting that even small daily commitments can lead to substantial improvements in emotional resilience and quality of life.
Abstract
Abstract not available from OpenAlex
Managing Chronic Pain: The Ketamine Option
CNS Drugs – October 16, 2025
Summary
Ketamine has shown significant promise in managing chronic refractory pain, particularly neuropathic pain, providing substantial short-term relief for many patients. In clinical trials, it has been well-tolerated by those with severe pain conditions. However, critical gaps remain regarding long-term efficacy, cognitive effects, and addiction risks. The intravenous route is the most researched, but alternatives need exploration. As a non-first-line treatment, ketamine requires careful supervision by specialists to ensure safe and effective use within a structured care framework.
Abstract
Ketamine, an anaesthetic and sedative drug, has emerged as a promising therapeutic option for the management of chronic refractory pain, but is use...
Economic evaluation of subcutaneous ketamine injections for treatment resistant depression: A randomised, double-blind, active-controlled trial - The KADS study.
Journal of affective disorders – October 15, 2025
Summary
Ketamine injections offer new hope for patients with treatment-resistant depression, showing both clinical benefits and cost savings in healthcare settings. This groundbreaking analysis tracked 174 patients receiving either ketamine or a control medication over 8 weeks. Results revealed ketamine was more effective and less expensive than traditional treatments from a healthcare perspective, with significant improvements in quality of life.
Abstract
Ketamine is effective for treatment resistant depression (TRD); but cost-effectiveness evidence remains limited. To evaluate the cost-effectiveness...
Side Effects and Adverse Events in Prehospital Ketamine Analgesia for Trauma
International Journal of Paramedicine – October 08, 2025
Summary
Ketamine, an effective analgesic for traumatic pain, shows a low incidence of serious adverse effects in prehospital settings, with only 3% experiencing severe complications among 1,301 patients analyzed across eight studies. Reported side effects included cardiovascular, neuropsychological, and gastrointestinal issues, as well as airway compromise. Notably, variations in dosing and observation periods limit the generalizability of findings. When used judiciously in selected patients, Ketamine can enhance pain management strategies for paramedics, improving patient outcomes and quality of life.
Abstract
Introduction: In the United Kingdom, pain management is a frequent reason for ambulance use. The benefits of adequate pain management are well docu...
Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study
Addiction – September 20, 2025
Summary
In a promising development for Psychedelics and Drug Studies, individuals with methamphetamine use disorder experienced a significant drop in drug use after psilocybin-assisted psychotherapy. Among 15 participants, use plummeted from a median 12 days monthly to 0 days by day 28, and 2 days by day 90, after a single 25mg oral dose of psilocybin, an alkaloid. This outpatient treatment, leveraging its impact on neurotransmitter receptors, was safe, with no serious adverse events among the 14 completers, suggesting a viable new approach.
Abstract
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we asse...
Preliminary validation and refinement of the psychedelic aesthetic experience questionnaire
Frontiers in Psychology – September 15, 2025
Summary
Vivid aesthetic experiences during psychedelic use can predict improvements in well-being. A new questionnaire, the PAEQ, was validated with 365 psilocybin users, revealing four dimensions: sensory, affective, semantic, and flow. The PAEQ demonstrated high reliability (α=0.90) and strong correlations with existing measures (e.g., r=0.69). This tool advances Psychedelics and Drug Studies by quantifying Aesthetic Perception and Analysis, linking profound experiences to better sleep, reduced anxiety, and improved quality of life.
Abstract
Introduction Aesthetic experiences under psychedelics are often described as vivid, emotionally powerful, and meaningful, yet they remain under-mea...
Psychedelic-Assisted Therapy in Palliative Care-Insights from an International Workshop.
Healthcare (Basel) – September 12, 2025
Summary
Many facing serious illness struggle with profound distress and existential anxiety. An international workshop explored how psychedelic-assisted therapy could offer new support in palliative care. Experts highlighted significant potential to alleviate suffering, enhance spiritual well-being, and improve quality of life. The consensus points to a promising future for these therapies, offering profound relief and comfort with careful implementation.
Abstract
Psychedelic-Assisted Therapy in Palliative Care-Insights from an International Workshop.
Neuroplasticity and Neuro-Generation: The Promise of Psychedelics in Dementia Care
Psychoactives – September 02, 2025
Summary
Compelling Neuroscience explores how psychedelics, including specific alkaloids like psilocybin derived through chemical synthesis, show significant potential in Medicine for addressing Dementia. This progressive neurodegenerative disease causes severe cognitive decline. Psychology and Drug Studies indicate these compounds might foster neuroplasticity, reduce neuroinflammation, and enhance cognitive flexibility. Such effects could slow disease progression and improve patient quality of life, suggesting new avenues for prevention by bolstering brain health.
Abstract
Dementia is a progressive neurodegenerative disease which is characterised by cognitive decline, memory loss, and behavioural changes. Patients suf...
Psilocybin-Assisted Psychotherapy for Chronic Somatoform Pain Disorder: A Case Report
Psychoactives – September 01, 2025
Summary
A patient suffering chronic pain and recurrent depression experienced significant relief following four sessions of psilocybin-assisted psychotherapy. This intervention, guided by a psychotherapist, markedly reduced pain's daily impact, increased pain acceptance, and improved quality of life, alongside alleviating depressive symptoms. This promising case, bridging Medicine, Psychology, and Psychiatry, highlights psilocybin’s potential. Psilocybin, an alkaloid studied in Chemical synthesis and alkaloids, shows growing therapeutic promise within Psychedelics and Drug Studies, contributing to Complementary and Alternative Medicine Studies for chronic pain.
Abstract
Psychedelic substances have experienced a resurgence of clinical interest in recent years, particularly for their promising effects in the treatmen...
Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis
Translational Psychiatry – August 29, 2025
Summary
Psilocybin-assisted therapy (PAT) shows promise for treatment-resistant depression, a major depressive disorder. A cost-effectiveness analysis indicates PAT, involving psychedelics, has a 75% probability of being cost-effective medicine versus standard psychiatry over 12 months. At $5000, PAT adds 0.031 Quality-adjusted life years (QALYs) and $3639 in costs. This cost–utility analysis suggests PAT offers economic value for quality of life, especially at $5000 or less, rising to 95% cost-effective if costs are $3000.
Abstract
Abstract Psilocybin-assisted therapy (PAT) has been shown in early trials to reduce the symptoms of treatment-resistant depression (TRD). This stud...
Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial
Journal of Psychopharmacology – August 29, 2025
Summary
A compelling clinical trial suggests psilocybin, a potent hallucinogen, significantly reduces traumatic stress. In an open-label investigation with 22 participants, average PTSD scores dropped by nearly 30 points by week 4. The drug demonstrated good tolerability; 91.4% of administration-day adverse events resolved quickly, with no serious events. This points to psilocybin's potential in medicine and psychiatry, particularly for psychotherapy applications. Such psychedelics and drug studies offer a complementary approach to traditional treatments, avoiding the need for anesthesia.
Abstract
Background: Post-traumatic stress disorder (PTSD) is a debilitating condition for which there are few efficacious treatments. Psilocybin is being s...
Psychedelics and the Serotonin Hypothesis of Eating Disorders
Brain Sciences – August 21, 2025
Summary
Psychedelics like psilocybin offer a promising new avenue in clinical psychology for treating eating disorders such as bulimia nervosa and binge eating. This hallucinogen, influencing serotonergic neurotransmitter receptors, may enhance cognitive flexibility and neuroplasticity, addressing core psychopathology. Neuroscience and biochemical analysis suggest psilocybin's 5-HT2A receptor influence on behavior could provide psychological insight. Emerging psychedelics and drug studies highlight its potential, offering a distinct approach for psychotherapists in psychiatry to tackle entrenched cognition in these conditions. Preliminary evidence suggests improved symptoms and quality of life.
Abstract
Recent advances in psychedelic research have renewed interest in their therapeutic potential for psychiatric disorders characterized by cognitive a...
AYAHUASCA E SAÚDE MENTAL
Revista Práxis em Saúde. – August 18, 2025
Summary
Ayahuasca shows promising therapeutic effects on mental health, particularly in alleviating depression and anxiety. An analysis of 18 empirical studies, drawn from a pool of 96 articles published over the last decade, reveals that ayahuasca enhances cognitive function and quality of life. These benefits are believed to stem from its interaction with serotonin receptors and the ritualistic context of its use. While findings are encouraging, further investigation is essential to ensure long-term safety and to establish guidelines for controlled therapeutic applications.
Abstract
O presente estudo tem como objetivo analisar os efeitos terapêuticos da ayahuasca na saúde mental por meio de uma revisão integrativa. Para isso, f...
Role of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and psychedelics in the treatment of major depressive disorder: A perspective on mechanistic insight and current status.
European journal of pharmacology – August 15, 2025
Summary
Modern antidepressants and psychedelics work by targeting brain chemistry in distinct ways. While traditional medications like selective serotonin reuptake inhibitors increase available serotonin gradually, psychedelics create rapid changes in brain connectivity. Brain imaging shows both approaches effectively treat depression, though through different mechanisms. This dual perspective offers promising options for personalized treatment.
Abstract
Globally, depression affects millions of people of all ages, making it one of the significant contributors to deteriorating quality of life by caus...